

Giovanni Germano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7989415/publications.pdf>

Version: 2024-02-01

33
papers

4,552
citations

361413

20
h-index

526287

27
g-index

34
all docs

34
docs citations

34
times ranked

9513
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. <i>Journal of Leukocyte Biology</i> , 2009, 86, 1065-1073.	3.3	1,202
2	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. <i>Cancer Cell</i> , 2013, 23, 249-262.	16.8	721
3	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	27.8	480
4	Cytokines as a key component of cancer-related inflammation. <i>Cytokine</i> , 2008, 43, 374-379.	3.2	292
5	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. <i>Cancer Research</i> , 2010, 70, 2235-2244.	0.9	251
6	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. <i>Nature Medicine</i> , 2018, 24, 961-967.	30.7	244
7	Chemokines in cancer related inflammation. <i>Experimental Cell Research</i> , 2011, 317, 664-673.	2.6	191
8	Cancer-promoting tumor-associated macrophages: New vistas and open questions. <i>European Journal of Immunology</i> , 2011, 41, 2522-2525.	2.9	179
9	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 13665.	12.8	170
10	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. <i>Cell Reports</i> , 2015, 12, 1978-1985.	6.4	163
11	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	143
12	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. <i>Cancer Discovery</i> , 2018, 8, 1518-1528.	9.4	77
13	Tumor-Associated Macrophages as Incessant Builders and Destroyers of the Cancer Stroma. <i>Cancers</i> , 2011, 3, 3740-3761.	3.7	73
14	RaLP, a New Member of the Src Homology and Collagen Family, Regulates Cell Migration and Tumor Growth of Metastatic Melanomas. <i>Cancer Research</i> , 2007, 67, 3064-3073.	0.9	69
15	Trabectedin. <i>Onc Immunology</i> , 2013, 2, e24614.	4.6	49
16	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. <i>Genome Medicine</i> , 2019, 11, 42.	8.2	42
17	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 80-83.	2.3	40
18	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	9.4	37

#	ARTICLE	IF	CITATIONS
19	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2 ⁺ and CCR5 ⁺ IFN γ -producing γ T cells in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L1010-L1025.	2.9	32
20	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	3.7	32
21	Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine, 2011, 43, 581-593.	3.8	19
22	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
23	New activities for the anti-tumor agent trabectedin: taking two birds with one stone. Oncotarget, 2013, 4, 496-497.	1.8	9
24	Inactivation of DNA repair“ prospects for boosting cancer immune surveillance. Genome Medicine, 2018, 10, 91.	8.2	8
25	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	3.4	6
26	Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncology Reports, 2007, 17, 17-23.	2.6	6
27	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
28	Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncology Reports, 0, , .	2.6	1
29	SP-0453 Targeting DNA repair to improve immunosurveillance and restrict cancer growth. Radiotherapy and Oncology, 2019, 133, S235-S236.	0.6	0
30	Abstract PR13: Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth. , 2017, , .		0
31	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0
32	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
33	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0